Top broker says buy CSL stock while trading on 'cheapest multiple in a long time'

Could the CSL share price go higher?

| More on:
Two happy scientists analysing test results in a lab

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL is a "recession-proof" stock according to one analyst 
  • CSL reported record plasma collections in the first half of 2023 
  • CSL shares are relatively flat on the market today 

CSL Limited (ASX: CSL) has fallen slightly on the stock market in the last month, but could now be the time to pounce?

CSL shares have descended 0.84% since market close on 4 April and are fetching $290.81 a piece at last look. In today's trade, CSL shares are 0.03% in the red. For perspective, the S&P/ASX 200 Index (ASX: XJO) is rising 0.01% today.

Let's take a look at the outlook for CSL stock going forward.

What's ahead?

CSL is a global biotechnology company that operates a huge plasma collection network along with developing a range of life-saving therapies and vaccines.

CSL is one of multiple "recession-proof" shares according to Airlie Funds Management head of Australian equities Matt Williams.

Williams noted CSL's collection costs are falling and could go down even more. In quotes provided to The Australian, Williams said:

During Covid, the cost of collecting plasma went up significantly. Those costs are
now reducing and in fact, a recession should actually lead to lower collection costs
because they won't have to pay their blood donors as much.

CSL is absolutely in that basket of recession-proof stocks. It's trading on a similar
multiple to Woolworths but it's actually the cheapest multiple I've seen it for a long
time.

CSL reported a net profit of US$1.62 billion in the first half of the 2023 financial year. The company noted plasma collections were at record levels.

Meanwhile, the team at Morgans has also recently placed an add rating on CSL shares with a $337.92 price target. This implies an upside of about 16% based on CSL's current share price.

Analysts are optimistic plasma collections will lift and more people will take the flu vaccine. Morgans said:

A key portfolio holding and key sector pick, we believe CSL is poised to break-out this year, a COVID exit trade, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares offering good value trading around its long-term forward multiple of ~30x.

CSL share price snapshot

The CSL share price has lifted nearly 9% in the last year.

CSL has a market capitalisation of about $140 billion based on the current share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Resmed share price higher despite CEO hitting sell on 14,683 shares

ResMed's CEO just sold $4.8 million worth of his own company's shares.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why this high-flying ASX 200 healthcare stock just crashed 11%

Neuren Pharmaceuticals just dropped its 1Q FY24 report on DAYBUE sales.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Bell Potter says this ASX biotech stock could rocket 80%

Investors with a high tolerance for risk may want to check out this stock.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

This ASX 200 healthcare stock is rocketing 8% following a record month!

Investors are impressed with this update. Here's why.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 reasons CSL stock is a great long-term investment

CSL has been a high-performing stock. Is it a buy today? UBS has the answer.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Down 10% since mid-March, are Medibank shares a buy or a sell?

Is this stock a healthy opportunity?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Which ASX 200 healthcare share with AI upside just hit a new 52-week high?

And top broker Goldman Sachs says the share price can go even higher.

Read more »

Emotional euphoric young woman giving high five to male partner, celebrating family achievement, getting bank loan approval, or financial or investing success.
Share Gainers

If you invested $8,000 in Mesoblast shares at the beginning of 2024, guess how much you'd have now!

Mesoblast shares have been soaring higher over the past six weeks. But why?

Read more »